Thank you.
My next question is this. You mentioned something about there being a new approach to developing drugs so, of course, that has evolved. One of the criticisms of our budget—and I think Mr. Balsillie said this yesterday, and I'm paraphrasing him to a certain extent—is that it's like we have set up an old way of funding and supporting industry, but we have 21st-century problems. We have put in $2.2 billion for the biomanufacturing and life sciences sector.
As we're setting up the programs, and as we're setting up the flow of funding, how would you say we could make sure we're setting it up in a way that is going to ensure we are supporting Canadian companies in this new approach of developing drugs?